1. Merck turns to contract manufacturers to help with Gardasil supply — Takeda looking at 24 new drug approvals by 2024 — AstraZeneca commits to being carbon negative by 2030 — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Minerva vs NovaSure

Discussion in 'Minerva Surgical' started by anonymous, Apr 24, 2018 at 4:35 AM.

  1. anonymous

    anonymous Guest

    Don't hold your breath waiting for a response, especially since you're asking for specifics.
  2. anonymous

    anonymous Guest

    As expected, crickets from the keyboard hero when pressed for specifics. Predictable.
  3. anonymous

    anonymous Guest

    lmao yeh im sure investors waste their time trolling on here. cafepharma is filled with bitter reps and overbearing managers. my guess is you are the latter.
  4. anonymous

    anonymous Guest

    Watch the 'Drug Short/Pharma bro' episode of 'Dirty Money' on Netflix.

    The top short-seller Fahmi Quadir, speaks of her using the forums on CafePharma to get an idea on what companies to bet against.

    Pretty naive, if you think that all the iceberg tips of secrets, and representative rumours that surface here are ignored by investors ;)
  5. anonymous

    anonymous Guest

    Watch the Netflix 'Dirty Money' documentary, 'Drug Short' episode on Pharma Bro/Valeant.

    Top short-seller Fahmi Quadir quotes researching Cafe Pharma when deciding what companies to bet against.

    Pretty naive if you think investors ignore the revealing rumours and iceberg-tip secrets that are revealed here ;)
  6. anonymous

    anonymous Guest

    As I keep saying, I don't work for either company and am no longer a HOLX share holder. I am not an analyst or some huge investor - I am a sales rep in a completely different segment of healthcare but I dabble in investing in certain stocks in the industry.

    What you aren't smart enough to realize is I actually want Minerva and other competitors to do some damage to Hologic across all divisions so the stock gets punished a bit and I can seize on another buying opportunity. On top of that, I've always been a believer that start-ups drive the innovation, I personally prefer small companies, and therefore I root for companies like Minerva in a David vs. Goliath battle where I think the big company gets lazy and stops investing in development. I read quite a bit on CP about companies I'm following or ones I'm invested in and it's actually not a waste of time. I've uncovered quite a bit of info here over the years that I wouldn't have found using other methods.

    By the way, I'm still waiting for specifics of where you thought I was wrong related to the studies and re-submitting things to the FDA. Funny how you've gone quiet on that.
  7. anonymous

    anonymous Guest

    Minerva might as well be a D+ NovaSure, no safety shutoff during treatment, no monitoring the integrity of the cavity, this thing, unfortunately, has fooled some very intelligent doctors who simply do not have the time to go through BS studies to figure out how bogus they really are. Despite the cherry-picked studies, Minerva's technology is not groundbreaking or specific to any patients needs. It is like Therma-choice came back to the market in a much more dangerous way.